Agilent Completes Acquisition of Dako | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has completed the acquisition of Dako for $2.2 billion in cash.

Agilent signed the deal to acquire the Danish cancer diagnostics firm last month and said at the time that it would fund the acquisition entirely with its off-shore cash. The acquisition provides Agilent with Dako's immunohistochemistry products and a growing companion diagnostics business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.